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Abstract. 
Background: Conventional treatment of acute promyelocytic leukemia (APL) including 
all-trans retinoic acid (ATRA) with anthracycline had led to good patient response and sur-
vival. However, instances of relapse continue to occur, and remain the major problem with 
this course of treatment. 
Patients and Methods: We collected the data of patients with newly diagnosed APL for the 
period 2004 to 2014, retrospectively. Data analysis included age, sex, initial white blood cell 
(WBC) count, coagulopathy and PML-RARα subtype. We also correlated PML-RARα fusion 
transcript level during treatment with outcome.  
Results: A total of 33 patients were ultimately included in this study. Twenty-nine patients 
achieved complete hematologic remission(CHR) and 24 patients achieved complete molecular 
remission(CMR). The median overall survival duration was 92.8 months. Patient relapse and 
initially high WBC count were 2 factors associated with poor survival (P = 0.003; P = 0.015). 
Eight patients relapsed and the relapse-free survival (RFS) was 41.8 months. A reduction ex-
ceeding 4 log of PML-RARα transcript level after induction and undetectable PML-RARα 
transcript after treatment was associated with better RFS (P = 0.028). 
Conclusions: Deeper molecular response after induction therapy was associated with a reduc-
tion in relapse and could be used to predict risk of relapse in newly diagnosed patient under 
conventional treatment. 
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中文摘要 
背景：急性前骨髓性白血病(APL)在現今結合全反式 A 酸及 Anthracycline 類藥物的治療
下，已有不錯的成績。但仍有部分病人產生復發進而導致死亡，本研究回顧近 10 年在本
院治療的 APL 病人，分析診斷時的各項因子(年齡、性別、白血球數等)並追蹤治療過程
中 PML-RARα融合基因量的變化，分析其與預後之關係。 
方法&結果：共 33 位病人於本院治療，其中 29 位達到血液完全緩解，24 位達完全分子
生物學緩解。平均存活時間為 92.8 月。不良預後因子分別為診斷時高的白血球數(P=0.015)
及復發(P=0.003)。8 位病人復發，無復發存活期為 41.8 個月。誘導治療後 PML-RARα轉
錄值下降大於 4.0log 或測不到為一好的預後因子(P=0.028)。 
結論：復發在 APL 預後上至為關鍵，而誘導治療後較深的分子生物學反應意味著較少的
復發，因此可視為一個好的預測因子。 
 
關鍵字: 急性前骨髓性白血病、PML-RARα、復發 
 
INTRODUCTION    
By using PML-RARα fusion transcription, APL 
could be a good model for residual disease (MRD) 
monitoring [1,2]. Post consolidation MRD monitoring 
had been regarded as an important component of in-
ternational guidelines for the management of APL 
[3,4]. However, the clinical implication of early mo-
lecular response after induction still needs to be de-
fined. 
Therefore, we performed this retrospective review 
in our hospital. The aim was to define the prognosis of 
APL patient under conventional therapy and stratified 
risk for relapse using quantification of PML-RARa 
transcript. 
 
PATIENTS AND METHODS 
 
Patients and Samples 
From February 2004 to September 2014, we col-
lected data from patients with newly diagnosed APL 
retrospectively in our center. The diagnosis of APL 
was made by morphology, immunophenotype, and 
cytogenetic determination. Some diagnoses were also 
confirmed by RT-PCR for PML-RARα rearrangements.  
If a patient obtained complete hematologic remis-
sion after induction, we checked (RQ-PCR) for 
PML-RARα transcript levels from bone marrow sam-
ples at 3 different time points: after induction, during 
consolidation and after consolidation therapy. 
 
Treatment Protocol 
Our treatment protocol was based on the APL-99 
protocol, which included an induction with ATRA 
plus idarubicin or daunorubicin and two to three con-
solidation courses with idarubicin, followed by a 
maintenance phase with ATRA, methotrexate and 
mercaptopurine for 2 years. ATRA would be added in 
those cases where the initial WBC count was higher 
than 10000/L during the consolidation phase.  
 
RQ-PCR Assay 
Quantification of the PML-RARα transcripts was 
performed according to the Europe Against Cancer 
program protocols [5,6]. The assays were run on an 
ABI PRISM 7700 or 7900 DNA sequence Detection 
System. Fusion transcripts were normalized with 
ABL17. All samples were tested in duplicates, and the 
results were reported according to the Europe Against 
Cancer guidelines as the normalized copy number, 
derived by multiplying the PML-RARα copy num-
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ber/ABL copy number ratio by 100.   
 
Definition and Statistical Analysis 
Hematologic remission was defined as normal 
bone marrow cellularity with <5% leukemic promye-
locytes and normalization of peripheral blood counts. 
Consequently, relapse was defined as the reappear-
ance of 5% leukemic promyelocytes in the bone mar-
row. Relapse-free survival (RFS) was calculated from 
the time CR was achieved to the patient’s last fol-
low-up or an event defined as hematologic relapse.  
Molecular remission (MR) was defined using 
quantitative RT-PCR (RQ-PCR) to detect PML/RARα 
transcript levels. Early molecular response is defined 
as a more than 4 log reduction after induction therapy, 
and complete molecular remission (CMR) as more 
than 5 log reduction, or undetectable.  
Relapse-free survival (RFS) for analysis after 
Table 1. Analysis of factors associated with overall survival 
 Patient number Median O.S. P value 
Initial WBC count (/L)    
<=10000 
>10000 
22 
11 
108 (85.6-118.4) 
68.5 (29.2-101.7) 
0.015 
Platelet    
 <= 30000 
>30000 
16 
17 
80.9 (56.6-105.5) 
103.6 (85.2-112.0) 
0.204 
DIC    
Yes 
No 
18 
15 
102.1 (81.9-112.4) 
91.5 (54.7-105.6) 
0.544 
Age    
>60 
<60 
5 
28 
74 (29.3-119.2) 
101 (72.8-112.9) 
0.204 
Sex    
Male 
Female 
18 
15 
91.2 (57.7-107.5) 
99.4 (81.4-117.3) 
0.418 
PML isoform    
S (bcr3) form 
L (bcr1) form 
V (bcr2) form 
9 
15 
4 
53.7(42.9-64.6) 
83.6(70.5-96.6) 
86.9(38.2-135.7) 
0.412 
CHR    
Yes 
No 
29 
3 
106.8(87.2-116.2) 
0.3 (0.1-0.8) 
< 0.001 
Relapse    
Yes 
No 
9 
21 
36.7(23.7-72.8) 
Not reach 
0.003 
Maintenance  therapy    
ATRA plus chemotherapy 
ATRA only 
21 
9 
107.1(93.1-121.1) 
65.2(49.9-80.4) 
0.293 
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consolidation therapy was defined as the time between 
the achievement of complete remission and hematol-
ogy relapse or the last follow-up. OS was defined as 
the time from achievement of complete remission to 
death or last follow-up. The probabilities of RFS and 
overall survival (OS) were calculated using the 
Kaplan-Meier method and compared using the 
log-rank test. All tests were carried out with the SPSS 
14.0 program (SPSS, Chicago, IL, USA). 
 
RESULTS 
A total of 33 patients were included in this study 
with median follow-up time of 41 months, 18 were 
male and 15 were female with the median age of 44 
(range 20 to 77). The medium WBC count was 
2000/uL (range from 200/uL to 625000/uL) with a 
median platelet count of 28200/uL (range from 
3000/uL to 146000/uL), and 18 patients presented 
with disseminated intravascular coagulation (DIC) 
during diagnosis.  
 
Treatment Outcome 
After induction, 29 patients had achieved complete 
hematological remission (CR rate: 87.9%) and 4 pa-
tients died during the induction period, (1 died of DIC 
and cranial hemorrhage, 1 died of myocardial infarc-
tion and 2 died of infection).   
The PML/RARA transcription level was monitored 
in 24 patients during treatment. After induction, 11 
patients were early molecular responders (>4.0 log) 
and 2 of them got CMR. At the end of consolidation, 
23 patients got CMR and the rest (1) also had good  
Table 2. Analysis of factors associated with relapse free survival 
 Patient number Relapse-free survival P value 
Initial WBC count    
>10000 
<=10000 
8 
21 
30.9 (20.5-41.4) 
40.4 (32.3-48.6) 
0.964 
DIC    
Yes 
No 
15 
14 
30.1 (23.3-36.9) 
44.0 (34.2-53.9) 
0.405 
Maintenance therapy    
Yes  
No  
21 
9 
40.8(32.2-49.5) 
30.3(21.5-39.2) 
0.886 
Molecular response checked during 3 treatment phases 
Post induction    
>4 log 
<=4 log 
8 
16 
Not reach 
31.4(23.8-38.9) 
0.024 
During consolidation    
CMR  
Non CMR 
9 
15 
42.8(33.3-52.3) 
27.2(20.1-38.2) 
0.521 
Before maintenance    
No CMR 
CMR 
1 
23 
10 
42.0 (34.7-50.3) 
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Figure 1. Relapse-free survival (RFS) of patients with different molecular response checked at different time 
points during therapy (A) After induction (B)During consolidation 
P=0.024 
P=0.337 
>4.0 log
<=4.0 log
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molecular response (more than 4.0 log reduction). All 
of the early responders got CMR after consolidation 
therapy was completed.  
The medium overall survival duration was 92.8 
months, with 5-year overall survival of 80%. The 
univariant analysis showed that high WBC count (p = 
0.015) and relapse (p = 0.007) were significantly as-
sociated with poor outcome; contrarily, those with 
CHR after induction had better outcome (p<0.005) 
(Table 1). 
Eight patients relapsed after CHR at a median of 
14 months (range 5–21 months). The RFS was 41.8 
months. Poor prognostic factors such as high initial 
WBC count and DIC are not related to RFS. Mainte-
nance therapy didn’t improved RFS, either (Table 2). 
The early responders and those with CMR after 
consolidation ended were associated with better RFS 
(Figure 1A). But those patients who achieved CMR 
during consolidation showed no benefit in RFS (Fig-
ure 1B).  
 
DISCUSSION 
An Initially high WBC count upon diagnosis was 
regarded as a poor outcome for APL[7]. Besides high 
WBC count, we had also found that relapse was asso-
ciated with worse OS and CHR and with better OS. 
Patients with early molecular response with more than 
4 log reduction post induction chemotherapy were 
associated with better RFS. 
The detection of PML-RARα by RQ-PCR becomes 
an important tool for monitoring MRD in patients 
with APL[3,8-10]. Early molecular response had also 
been proven as a predictor of better outcome in certain 
specific hematologic malignancy, such as newly di-
agnosed CML under TKI therapy[8]. 
In APL, however, the kinetics of tumor burden 
reduction (log-reduction between diagnosis and 
post-induction) did not correlate with disease out-
come[9]. These results contrast with other leukemic 
disorders such as t(9;22) CML or t(8;21) AML[10-12]. 
Such differences could be explained in part by the 
type of therapy, since ATRA, unlike other cytotoxic 
treatments, promotes the differentiation of APL cells 
instead of quickly eliminating leukemic cells. There-
fore, induction treatment of APL can be associated 
with delayed leukemic clearance [11]. 
However, two additional recent studies also found 
detection of PML-RARa at the end of the initial induc-
tion therapy correlates with subsequent risk of relapse 
in patients, especially those receiving Arsenic trioxide 
(ATO) therapy[13,14].  
Recently, a phase II study demonstrated the out-
standing treatment featuring ATO and autologous 
hematopoietic stem cell transplantation for relapsed 
APL, where 5-year event-free and overall survival 
rates were 65% and 77%[15]. This same treatment 
also showed benefit in our patients. Among the 8 re-
lapse patients, 7 had received salvage chemotherapy 
with arsenic trioxide and all of them achieved com-
plete hematological remission. Three of them had fur-
ther received autologous stem cell transplantation and 
got CMR. The other patient received reinduction with 
duonorubicin plus cytarabine but died of neutropenia.  
The role of maintenance therapy in newly diag-
nosed APL had been an often-debated issue [3,16]. All 
of our patients received maintenance therapy after 
complete remission and 21 of them had received both 
chemotherapy and ATRA. However, there appeared to 
be no survival benefit from adding chemotherapy in 
maintenance. 
The limitation of this study was the relatively 
small patient number. Another study had pointed out 
that FLT3-ITD mutation was also a poor prognostic 
factor[17], which was also lacking in our study.   
In conclusion, our study showed that initial high 
WBC count and relapse were 2 major factors associ-
ated with poor prognosis and early mortality in pa-
tients undergoing conventional ATRA plus chemo-
therapy treatment. Early and deep molecular response 
after induction chemotherapy predicts reduced relapse 
and was a good prognostic factor. 
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